CRAWFORD & COMPANY

NYSE: CRD-A (Crawford & Company)

Last update: 10 May, 8:54PM

9.28

-0.28 (-2.93%)

Market Trend

Short Term Medium Term
Industry Insurance Brokers (US) Mixed Bullish
Insurance Brokers (Global) Mixed Bullish
Stock Crawford & Company Bearish Bullish

Similar Stocks

Stock Market Cap DY P/E P/B
CRD-A 467 M 2.89% 20.62 3.17
CRD-B 455 M 2.87% 20.49 3.16
SLQT 345 M - - 1.37
MMC 102 B 1.38% 26.22 8.15
AON 57 B 0.88% 22.78 -
AJG 51 B 0.96% 47.37 4.85

Crawford & Co provides claims and outsourcing solutions to the risk management, insurance industry, and self-insured entities. Its segments include North America Loss Adjusting; International Operations; Broadspire and Platform Solutions. The company generates maximum revenue from the International Operations segment. International Operations segment provides claims management and adjusting services to insurance carriers and self-insured entities related to property and casualty insurance claims.

Sector Financial Services
Industry Insurance Brokers
Investment Style Small Value
52 Weeks Range
7.55 - 13.68
High 11.00 (Barrington Research, 18.53%) Buy
Median 11.00 (18.53%)
Average 11.00 (18.53%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
Barrington Research 11 Mar 2024 11.00 (18.53%) Buy 7.92

No data within this time range.

Date Type Details
17 May 2024 Announcement Agilent to Participate in Jefferies Global Healthcare Conference
16 May 2024 Announcement Agilent Presents Solutions Innovation Research Awards to Cornell and Indiana University Researchers
02 May 2024 Announcement Agilent to Announce Second-Quarter Fiscal Year 2024 Financial Results May 29
01 May 2024 Announcement Padraig McDonnell Assumes Agilent CEO Role
01 May 2024 Announcement Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution
29 Apr 2024 Announcement Agilent Names Simon May to Lead Diagnostics and Genomics Group
16 Apr 2024 Announcement Agilent Receives Scientists' Choice Awards for Sustainability
15 Apr 2024 Announcement Agilent Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay
04 Apr 2024 Announcement Agilent Brings Great Science to Life at Analytica 2024
03 Apr 2024 Announcement Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics
02 Apr 2024 Announcement Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence
01 Apr 2024 Announcement Agilent Launches New Advanced Dilution System to Increase Lab Efficiency
14 Mar 2024 Announcement Agilent Presents 2024 Darlene Solomon Award to University of Cambridge Researcher Joycelyn Tan
29 Feb 2024 Announcement Agilent Presents Solutions Innovation Research Awards to Drexel University and Prairie View A&M University Researchers
27 Feb 2024 Announcement Agilent Reports First-Quarter Fiscal Year 2024 Financial Results
21 Feb 2024 Announcement Agilent Announces Cash Dividend of 23.6 Cents per Share
21 Feb 2024 Announcement Agilent CEO Mike McMullen to Retire; Agilent CrossLab Group President Padraig McDonnell Named CEO-Elect
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No data